论文部分内容阅读
喘息是5岁以下儿童常见的临床疾病,其发生率逐年上升。而尽早对5岁以下反复喘息患儿进行适当治疗,可保护患儿肺功能,降低其日后发展为儿童哮喘的可能性。吸入性糖皮质激素(inhaled glucocorticoids,ICS)在儿童喘息性疾病的防治中已有广泛应用,但由于5岁以内儿童喘息的病因复杂,疾病的转归常不可预测,因此对ICS在其临床实际应用中的评价存在不同意见。本文就ICS在婴幼儿喘息性疾病中的应用地位及安全性做一简要叙述。
Breathing is a common clinical disease in children under 5 years of age, and its incidence increases year by year. As soon as possible for children under 5 years of repeated wheezing with appropriate treatment can protect children with lung function and reduce the possibility of their future development for children with asthma. Inhaled glucocorticoids (ICS) have been widely used in the prevention and treatment of wheezing diseases in children. However, because the etiology of wheezing in children less than 5 years old is often unpredictable, the outcome of ICS in its clinical practice There are different opinions on the evaluation of the application. This article gives a brief account of the status and safety of ICS in asthmatic infants and young children.